EssilorLuxottica SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000121667
EUR
194.80
0.5 (0.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

579.34 k

Shareholding (Dec 2025)

FII

0.01%

Held by 6 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Strong Long Term Fundamental Strength with a 392.90% CAGR growth in Net Sales

  • Company has a low Debt to Equity ratio (avg) at times
2

With ROE of 0.00%, it has a Attractive valuation with a 2.51 Price to Book Value

3

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 89,299 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

33.44%

stock-summary
Debt Equity

0.21

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

2.30

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.88%
0%
-27.88%
6 Months
-28.3%
0%
-28.3%
1 Year
-27.66%
0%
-27.66%
2 Years
-7.61%
0%
-7.61%
3 Years
19.8%
0%
19.8%
4 Years
18.87%
0%
18.87%
5 Years
43.34%
0%
43.34%

EssilorLuxottica SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
392.90%
EBIT Growth (5y)
0
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
422.21
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
79.31%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
2.51
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
2.25
EV to Sales
36.40
PEG Ratio
NA
Dividend Yield
30.58%
ROCE (Latest)
ROE (Latest)

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by EssilorLuxottica SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.48% vs 4.38% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.93% vs 2.68% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28,491.00",
          "val2": "26,508.00",
          "chgp": "7.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,474.00",
          "val2": "6,571.00",
          "chgp": "-1.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "239.00",
          "val2": "254.00",
          "chgp": "-5.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-180.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,443.00",
          "val2": "2,491.00",
          "chgp": "-1.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "118.00%",
          "val2": "132.90%",
          "chgp": "-1.49%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
28,491.00
26,508.00
7.48%
Operating Profit (PBDIT) excl Other Income
6,474.00
6,571.00
-1.48%
Interest
239.00
254.00
-5.91%
Exceptional Items
0.00
-180.00
100.00%
Consolidate Net Profit
2,443.00
2,491.00
-1.93%
Operating Profit Margin (Excl OI)
118.00%
132.90%
-1.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 7.48% vs 4.38% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1.93% vs 2.68% in Dec 2024

stock-summaryCompany CV
About EssilorLuxottica SA stock-summary
stock-summary
EssilorLuxottica SA
Pharmaceuticals & Biotechnology
EssilorLuxottica SA, formerly known as Essilor International Compagnie Generale D Optique SA, is a France-based ophthalmic company. The Company designs, manufactures and markets a range of lenses, frames and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. The Company operates under a number of brands, including Ray-Ban, Oakley and Varilux, among others. The Company operates in Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.
Company Coordinates stock-summary
Company Details
147 rue de Paris , CHARENTON-LE-PONT None : 94220
Registrar Details